Journal
CANCER LETTERS
Volume 367, Issue 1, Pages 1-11Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.06.019
Keywords
Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance
Categories
Funding
- National Natural Science Foundation of China [81201942]
- Zhejiang Provincial Natural Science Foundation of China [LZ14H160002, LY15H160039]
Ask authors/readers for more resources
Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available